🇺🇸 efavirenz + emtricitabina + tenofovir in United States

15 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Dizziness — 2 reports (13.33%)
  2. Insomnia — 2 reports (13.33%)
  3. Malaise — 2 reports (13.33%)
  4. Nausea — 2 reports (13.33%)
  5. Vomiting — 2 reports (13.33%)
  6. Adrenergic Syndrome — 1 report (6.67%)
  7. Drug Interaction — 1 report (6.67%)
  8. Drug Withdrawal Syndrome — 1 report (6.67%)
  9. Exposure During Pregnancy — 1 report (6.67%)
  10. Live Birth — 1 report (6.67%)

Source database →

Other Infectious Disease / Virology approved in United States

Frequently asked questions

Is efavirenz + emtricitabina + tenofovir approved in United States?

efavirenz + emtricitabina + tenofovir does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for efavirenz + emtricitabina + tenofovir in United States?

Hospital Universitari Vall d'Hebron Research Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.